ABSTRACT
132The nonalcoholic fatty liver disease (NAFLD) is a component of metabolic syndrome and the mortality among NAFLD is higher than general population. NAFLD spectrum includes simple steatosis, steatohepatitis, fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure. It is important to recognize that underactivity, insulin resistance, lipotoxicity, adipokines, oxidative stress, overnutrition, genetic factors, and other inflammatory mediators have strong link to the development of NAFLD/NASH (Nonalcoholic Steatohepatitis). Treatment of fatty liver is crucial not only due to the possible progression to more aggressive liver diseases but also because it may cause cardiovascular diseases. Dietary regimen and exercise play an important role in the management of NAFLD. Ideal therapy or nutraceuticals for NAFLD must possess insulin-sensitizing, antioxidants, lipid-lowering, hepatic protective, and fat mass reducing effect.
